Mackenzie Financial
RARE icon

Mackenzie Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mackenzie Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,160
Closed -$697K – 1818
2025
Q2 		$697K Buy
19,160
+502
+3% +$18.1K ﹤0.01% 1115
2025
Q1 		$676K Buy
18,658
+2,543
+16% +$106K ﹤0.01% 1097
2024
Q4 		$678K Buy
16,115
+11,825
+276% +$587K ﹤0.01% 1050
2024
Q3 		$238K Buy
+4,290
New +$219K ﹤0.01% 1296

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Mackenzie Financial's RARE Position: Q3 2025 in Review

Mackenzie Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 19,160 shares — an estimated $697K sold.

Mackenzie Financial first reported a position in RARE in Q3 2024 and held it in 4 quarters. The position peaked at $697K in Q2 2025. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Mackenzie Financial reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Mackenzie Financial sold 19,160 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $697K.
  • Mackenzie Financial first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 4 quarters.
  • Mackenzie Financial's Ultragenyx Pharmaceutical position peaked at $697K in Q2 2025.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Mackenzie Financial's 13F filing for Q3 2025, filed 13 Nov 2025.